Podcasts about Igan

Martine Hackett returns with a new season of Untold Stories: Life with a Severe Autoimmune Condition. The best stories unite us, empower us, and help us push forward—against all odds. This season, we’re growing our community, and welcoming voices from myositis and IgAN to the fold. We are stronger, together.See omnystudio.com/listener for privacy information.

IgA nephropathy and IgA vasculitis remain complex and evolving areas in nephrology care. In this episode, experts discuss key insights from the KDIGO guidelines and KDOQI commentary published in AJKD, focusing on updated approaches to risk stratification, disease progression, and treatment decision making. The conversation highlights the role of supportive care, immunosuppressive therapy considerations, and emerging therapeutic options, while addressing variability in clinical practice and patient management challenges. This episode provides practical, evidence based perspectives to help clinicians navigate the nuances of IgAN and IgAV care and apply guideline recommendations in real world settings. Please view the AJKD article here.

CME credits: 0.25 Valid until: 30-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-upated-kdigo-clinical-practice-guideline-recommndations-to-maximize-proteinuria-reduction-in-patients-with-igan/26630/ Our experts review updated KDIGO practice guideline recommendations for proteinuria reduction in IgA nephropathy (IgAN) and their implications for clinical care. Drs. Chee Kay Cheung and Claudia Seikrit examine the shift toward lower proteinuria targets (

Žigan Krajnčan je vsestranski umetnik, plesalec, koreograf, pevec, glasbenik, igralec ... deluje na presečišču več vej umetniškega izraza. Glas, petje je njegovo močno izrazno orodje, ki ga povezuje z gibanjem, plesom. Uprizarja čutne odrske izkušnje. Pot ga je vodila tudi v tujino.

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-lower-proteinuria-levels-shifting-the-goalpost-in-igan/54686/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-guidelines-to-action-in-igan-embracing-a-simultaneous-dual-concordant-approach/54687/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major paradigm shift, lowering the optimal proteinuria target from

CME credits: 0.25 Valid until: 24-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/inside-the-igan-clinic-shared-decision-making-into-practice/26633/ Professor Jonathan Barratt illustrates the integration of shared decision-making in the management of IgA nephropathy while interacting with a real patient with IgAN, highlighting how patient-centered conversations about proteinuria, GFR, and blood pressure can guide individualized treatment strategies. Emphasis is placed on explaining diagnostic findings such as the Oxford MEST-C score, monitoring disease progression, and evaluating emerging therapeutic options, including SGLT2 inhibitors, RAS blockade, budesonide, and sparsentan. Considerations around lifestyle, medication adherence, side effects, and life planning—such as employment and family planning—are explored. This dialogue-driven format demonstrates how collaborative care supports sustainable treatment adherence and improves patient engagement.=

On this episode Fred Goldstein invites Ami Gopalan, Senior Vice President of Strategic Content and Growth Optimization at Precision AQ in a continion of AMCP's rare disease series with an in-depth look at IgA nephropathy (IgAN), a progressive autoimmune kidney disease that often goes undiagnosed until advanced stages. As a patient living with IgAN, Ami brings both a professional and personal perspective to the discussion as we explore the disease's silent progression, the burden it places on patients and families, the evolving treatment landscape, and how managed care can better incorporate patient value, clinical guidelines, and emerging evidence to support long-term outcomes. This podcast is supported by an independent medical education grant from Alexion and AstraZeneca Rare Disease. AMCP offers CPE for this podcast through December 31, 2026. For additional information and to claim credit, please visit: The Power of Partnership: Bridging Patients and Payers in IgA Nephropathy Management. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

CME credits: 1.00 Valid until: 28-12-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-new-paradigm-in-igan-managementadvancing-clinical-practice-in-the-era-of-therapeutic-expansion/54415/ On-demand webcast on the latest advances in diagnosing and managing patients with IgA nephropathy (IgAN), including the current data on new and emerging IgAN therapies.=

The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬ (COI)Sophia Ambruso @sophia-kidney.bsky.socialSwapnil Hiremath @hswapnil.medsky.social and on LinkedInSpecial Guests Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies)Editing and Show Notes byNayan Arora @captainchloride.bsky.socialThe Kidney Connection written and performed by Tim YauShow NotesProteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed)The number, quality, and coverage of randomized controlled trials in nephrology (PubMed 2004)A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction (PubMed 2017)BLISS Belimumab in lupus nephritis (NephJC | PubMed)The Phase 2 trial of atacicept A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy (PubMed)The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (PubMed | NephJC)The use of Gd-IgA1 in the Testing Trial Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy (PubMed)If you can't get enough Jon Barratt, take a look at his grand rounds at The University of Ottawa. Updates to the KDIGO Guidelines for the treatment of IgA nephropathy, with Prof Jonathan Barratt (YouTube)Tubular SecretionSwapnil Hiremath Pluribus on Apple TV (Wikipedia)Jon Barratt Lynyrd Skynyrd (Wikipedia) Slow Horses (Wikipedia) on AppleTVJoel Topf the new ASN

Alarming in immunoglobulin A nephropathy (IgAN): over 40% present late. Explore latest advancements in management of the most common cause of primary glomerulonephritis worldwide. Credit available for this activity expires: 12/23/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-challenges-igan-management-clinical-implications-2025a1000w9b?ecd=bdc_podcast_libsyn_mscpedu

Is your patient's proteinuria low enough? New KDIGO goals: target the immune cause and hit < 0.5 g/day to preserve kidney function.   Credit available for this activity expires: 12/2/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003055?ecd=bdc_podcast_libsyn_mscpedu

On this episode, host Fred Goldstein invites Dr. Kartik Kalra, Clinical Nephrologist at Geisinger Medical Center. We discuss IgA nephropathy and the newly released, comprehensive 2025 KDIGO guidelines. We explore what IgAN is, why diagnosis is often delayed, how it commonly presents, and the impact the disease can have over a patient's lifetime. Dr. Kalra also discusses what prompted the latest guideline revision, how thinking around IgAN has evolved, and what these changes signal for clinicians, health systems, and the managed care community. This podcast is supported by an independent medical education grant from Calliditas Therapeutics. AMCP offers CPE for this podcast through December 31, 2026. For additional information and to claim credit, please use the instructions provided here: ⁠AMCP Learn - claim CPE instructions https://amcplearn.org/sites/default/files/media/2024-10/AMCP%20Learn%20-%20Claim%20CPE%20Instructions_0.pdf Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Iganädalases poliitilises vestlussaates "Räägime asjast" räägivad asjadest nii, nagu need on, EKRE poliitikud Mart ja Martin Helme."Me ju hoiatasime - süvariik on olemas. Nüüd teab isegi Postimees, et süvariik on olemas, nüüd teavad isegi advokaadid, et süvariik on olemas. Ainult peaprokurör veel ei näe," tõdetakse esimese teemana. "Poliitikas pole suuremat pattu, kui sul on õigus liiga vara, mille eest meid nuheldakse kogu aeg," on Martin Helme sarkastiline, lisades, et madu, mida rinnal soojendanud, on hammustanud peremeest ehk Isamaa on saanud prokuratuurilt kahtlustuse.Teisena räägitakse üleüldisest vastutamatusest Metsküla kooli sulgemise näitel.Välisteemana võetakse luubi alla Ukraina sõja rahastamine, kus Belgia on pannud kanna maha, kus ollakse olukorras, kus Ameerika enam ei rahasta ja Euroopal raha ei ole. Sellega seoses märgitakse ka Kaja Kallase häbijadade jätkumist.  Vestlussaade “Räägime asjast” on TRE Raadios ja Ring FM-is eetris pühapäeval kell 11 – 12 ja kordus samal õhtul kell 21 – 22. Samuti saab saadet kuulata Uute Uudiste portaalis ja taskuhäälingu-keskkondades (Spotify, Apple podcasts, Mixcloud).

The FiltrateJoel Topf‍ ‍@kidneyboy.bsky.social‬ (COI)Sophia Ambruso @sophia-kidney.bsky.socialSwapnil Hiremath @hswapnil.medsky.social and on LinkedInSpecial Guests Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies)Editing and Show Notes byNayan Arora @captainchloride.bsky.socialThe Kidney Connection written and performed by Tim YauShow NotesProteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed)The number, quality, and coverage of randomized controlled trials in nephrology (PubMed 2004)Updated here (PubMed | NephJC discussion)A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction (PubMed 2017)BLISS Belimumab in lupus nephritis (NephJC | PubMed) The Phase 2 trial of atacicept A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy (PubMed)The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy (PubMed | NephJC)Christos' Bluesky post:https://bsky.app/profile/christosargyrop.bsky.social/post/3m5bsujwg3s2q The use of Gd-IgA1 in the Testing Trial Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy (PubMed)If you can't get enough Jon Barratt, take a look at his grand rounds at The University of Ottawa. Updates to the KDIGO Guidelines for the treatment of IgA nephropathy, with Prof Jonathan Barratt (YouTube)Tubular SecretionSwapnil Hiremath Pluribus on Apple TV (Wikipedia)Jon Barratt Lynyrd Skynyrd (Wikipedia) Slow Horses (Wikipedia) on AppleTVJoel Topf the new ASN

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve deep into a series of transformative events that underscore the dynamic nature of our industry, where scientific innovation meets regulatory evolution and market adaptation.We begin with significant regulatory news from Medicare, which recently announced price reductions for 15 prescription drugs, including Novo Nordisk's semaglutide products, Ozempic and Wegovy. This initiative is part of the Inflation Reduction Act aimed at making essential medications more affordable. By potentially increasing accessibility to these treatments, this move highlights a growing trend towards cost containment in drug pricing within the U.S. healthcare system. It reflects a broader effort to ensure that life-saving treatments remain within reach for more patients, emphasizing the need for balance between innovation and affordability.Turning to approvals, Otsuka has secured FDA clearance for Voyxact, a first-in-class treatment targeting IgA nephropathy (IgAN). This positions Otsuka in an increasingly competitive market space populated by major players like Novartis and Vertex. The entry of Voyxact could pave the way for innovative therapeutics in kidney diseases, offering new hope to patients who have had limited treatment options until now.On the other side of the Atlantic, French authorities have conducted a raid on Sanofi's headquarters as part of a tax fraud investigation. This development sheds light on ongoing scrutiny in the pharmaceutical sector regarding financial practices and regulatory compliance. Such investigations can have far-reaching implications on corporate governance and transparency, reminding us of the importance of ethical practices in maintaining industry trust.Novo Nordisk has strategically used its FDA national priority voucher to expedite the review process for a high-dose formulation of Wegovy. This move underscores the importance of regulatory incentives in accelerating drug development timelines, allowing for quicker patient access to potentially life-changing therapies. It's a testament to how strategic navigation through regulatory pathways can significantly impact drug availability.In clinical trials, Sarepta Therapeutics received FDA clearance to conduct a study combining its gene therapy Elevidys with sirolimus in patients with Duchenne muscular dystrophy. The study aims to address liver safety issues associated with Elevidys, which had led to previous label restrictions. This reflects the industry's commitment to enhancing therapeutic safety profiles while expanding treatment indications.In oncology advancements, AstraZeneca's Imfinzi received FDA approval for use in early-stage stomach cancer, marking its third perioperative indication. This approval underscores the expanding role of immunotherapy across various cancer types and stages, offering new treatment paradigms that could improve surgical outcomes and long-term patient survival.Despite these advances, there is skepticism regarding artificial intelligence's role in regulatory compliance submissions among pharmaceutical professionals. A survey reveals that 65% express distrust towards AI-generated outputs, highlighting challenges that AI technologies face in gaining acceptance within highly regulated environments such as pharmaceuticals. However, federal recommendations to revamp U.S. biotechnology research emphasize incorporating AI into scientific processes to maintain global competitiveness. This call reflects concerns over potential declines in innovation leadership and underscores the need for strategic investment in research infrastructure.In antitrust news, the Federal Trade Commission (FTC) outlined its case agaiSupport the show

CME credits: 0.25 Valid until: 19-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/ Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria treatment goal of

In this powerful Kidney Warrior Story, host Dee sits down with Tony to unpack a decade-spanning journey through chronic kidney disease (CKD)—from a shock Stage 4 diagnosis of IgA Nephropathy (IgAN) to Stage 5 kidney failure, peritoneal dialysis (PD) with brutal drain pain, a transition to haemodialysis (HD), line infection and coma, the courage to self-needle with a fistula, and ultimately the life-changing gift of a kidney transplant.   Tony shares the practical and emotional realities few hear about: choosing PD vs HD, APD (overnight machine) vs manual gravity bags, buttonhole vs rope-ladder needling, home haemodialysis training, fluid management, and rebuilding confidence after hospital trauma. He explains how movement and sport (from 5K Parkruns to half marathons) helped his mental health on dialysis—and how he kept going after FIVE “dry-run” transplant calls before finally receiving his match.   Post-transplant, Tony competed at the Transplant Games (bronze in cycling!), then faced a sudden cycling accident with a broken talus—and still came back stronger with kidney function over 90%. Tony's message? You're not alone. With support, information, and small, consistent steps, more is possible than you think.   WHAT YOU'LL HEAR • Early signs missed: high blood pressure and “white coat” assumptions  • Stage 4 to Stage 5 CKD: understanding IgA Nephropathy and next steps  • Peritoneal Dialysis (PD): APD vs gravity bags, real talk on drain pain  • Haemodialysis (HD): line infection → coma, then fistula and self-needling  • Buttonhole vs rope-ladder: how Tony overcame needle phobia  • Home HD routine + exercising safely on dialysis (5K to half marathons)  • Five transplant calls that didn't happen—coping tools that helped  • The call that changed everything: consent, surgery, waking the kidney  • Transplant Games success—and recovery after a serious cycling crash  • Mental health: therapy, peer groups, and why talking saves lives  • Practical tips: fluid limits, pacing activity, and building back slowly  • Community resources: Kidney Care UK, young adult kidney groups   KEY TAKEAWAYS • Movement is medicine—start with what you can manage (even 100 metres).  • Your effort matters—even when decline happens, you may be delaying harm.  • Build your circle: family, peers, clinicians, therapists, Kidney Care UK.  • Advocacy counts: read clinic posters, join groups, ask questions.  • Mindset + support = progress. Small daily actions add up.   If you're newly diagnosed or supporting someone with CKD, browse our back catalogue for in-depth episodes on PD, HD, transplant prep, and mental health.   Follow Diary of a Kidney Warrior:  

Iganädalases raadiosaates "Räägime asjast" räägivad asjast nii nagu need on muidugi Martin ja Mart Helme, seekord on kaasatud ka paar huvitavat saatekülalist.Kõigepealt ei saa üle ega ümber valimistest, täpsemalt e-valimistest. Telefonile võetakse digiõiguste aktivist Märt Põder, kes on tänavu ka ametlik e-valimiste vaatleja. Needsinased e-valimised on algusest peale muidugi  viltu vedanud ning pälvinud ka mitu kaebust nii Märt Põderi vedava MTÜ Ausad Valimised kui ka EKRE poolt.Valimistest räägitakse ka EKRE Tallinna volikogu fraktsiooni nõuniku, EKRE esinumbriga Nõmmel Kadri Vilbaga.Välisteemadest minnakse Euroopast nii Ameerika Ühendriikidesse kui ka Lähis-Idasse.Eesti otsekohesemaid ja teravamaid poliitilisi vestlussaateid “Räägime asjast” on TRE Raadios ja Ring FM-is eetris pühapäeval kell 11 – 12 ja kordus samal õhtul kell 21 – 22. Samuti saab saadet kuulata Uute Uudiste portaalis ja taskuhäälingu-keskkondades (Spotify, Apple podcasts, Mixcloud). Muidugi!

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN

CME credits: 0.25 Valid until: 03-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/real-world-igan-a-case-based-approach-to-maximizing-kidney-preservation/26635/ Join Drs. An de Vriese and Muh Geot Wong in a case-based discussion on optimizing long-term kidney outcomes in patients with IgA nephropathy (IgAN). Faculty review the new KDIGO guidelines, including more aggressive treatment targets such as proteinuria levels below 0.3 g/day. A clinical case is used to illustrate practical guideline application, highlighting the use of sparsentan in a patient with persistent proteinuria despite RAASi therapy. The faculty also explore combination treatment approaches, including SGLT2 inhibitors, and reference data from the SPARTAN and SPARTACUS studies. =

In this episode, we explore the evolving role of surrogate endpoints in the management of IgA nephropathy (IgAN), with a particular focus on the significance of estimated glomerular filtration rate (eGFR). Of the completed Phase 3 trials in IgAN, one used time-weighted average eGFR, an area under the curve-based measure that reflects the average change in eGFR from baseline over a specified period, in this case, over the full 2-year study period. The other trial used total eGFR slope to describe the overall rate of change over 2 years. But what do these endpoints mean outside the setting of a clinical trial? Expert insights shed light on how proteinuria and eGFR trends can inform prognosis and guide treatment decisions in clinical practice over the long term. Listeners will gain a deeper understanding of how to interpret eGFR changes over time and apply this knowledge to optimize patient care. Designed for nephrology professionals, this episode offers practical, evidence-based perspectives on integrating these surrogate endpoints into the care of patients with IgAN. Supported by Calliditas Therapeutics Upon completion of the podcast, please take a moment to complete a brief survey: https://kidneyforms.tfaforms.net/4728109

Can you recognize and manage immunoglobulin A nephropathy (IgAN)? Hear from patients and expert faculty on how breakthroughs in therapy could enhance patient outcomes. Credit available for this activity expires: 9/30/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/bridging-gap-case-based-exploration-current-and-emerging-2025a1000q1d?ecd=bdc_podcast_libsyn_mscpedu

Discover how emerging B-cell-targeted therapies are transforming the treatment landscape and outcomes for patients with IgA nephropathy (IgAN). Credit available for this activity expires: 9/18/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002833?ecd=bdc_podcast_libsyn_mscpedu

CME credits: 0.25 Valid until: 27-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-igan-care-achieving-lower-proteinuria-targets-with-combination-therapy/26631/ In this episode of Clinical Countdown, Professors Jonathan Barratt and Sydney Tang discuss the evolving treatment strategies for IgA nephropathy, focusing on lowering proteinuria through combination therapy. They examine differences in disease presentation across global populations and emphasize updated KDIGO guidance on aggressive proteinuria reduction targets. The discussion includes evidence from the PROTECT trial supporting sparsentan's efficacy as a dual endothelin–angiotensin receptor antagonist and considers the role of SGLT2 inhibitors based on outcomes from the DAPA-CKD and EMPA-KIDNEY trials. Our experts also review recent real-world data showing that when added to SGLT2 inhibitors and RAS blockade, sparsentan can significantly reduce proteinuria without notable safety concerns.=

CME credits: 0.25 Valid until: 27-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-igan-care-achieving-lower-proteinuria-targets-with-combination-therapy/26631/ In this episode of Clinical Countdown, Professors Jonathan Barratt and Sydney Tang discuss the evolving treatment strategies for IgA nephropathy, focusing on lowering proteinuria through combination therapy. They examine differences in disease presentation across global populations and emphasize updated KDIGO guidance on aggressive proteinuria reduction targets. The discussion includes evidence from the PROTECT trial supporting sparsentan's efficacy as a dual endothelin–angiotensin receptor antagonist and considers the role of SGLT2 inhibitors based on outcomes from the DAPA-CKD and EMPA-KIDNEY trials. Our experts also review recent real-world data showing that when added to SGLT2 inhibitors and RAS blockade, sparsentan can significantly reduce proteinuria without notable safety concerns.=

IgA nephropathy is often diagnosed late. Recognizing and referring patients timely improves management and outcomes. Credit available for this activity expires: 8/19/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002763?ecd=bdc_podcast_libsyn_mscpedu

Immunoglobulin A nephropathy (IgAN) unveiled: follow the B-cell pathway from mucosal misfire to glomerular damage and discover emerging strategies for smarter care. Credit available for this activity expires: 7/16/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/visual-insights-exploring-disease-modifying-effects-anti-2025a1000ihg?ecd=bdc_podcast_libsyn_mscpedu

BEST OF TST: Max Igan stops by in mid-2019 to talk with Ryan & cohost Jack about the notion that "Everything is a Lie"?*The is the FREE archive, which includes advertisements. If you want an ad-free experience, you can subscribe below underneath the show description.-FREE ARCHIVE (w. ads)SUBSCRIPTION ARCHIVEX / TWITTER FACEBOOKMAIN WEBSITECashApp: $rdgable EMAIL: rdgable@yahoo.com / TSTRadio@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-secret-teachings--5328407/support.

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk.  

Paul Williamson delivers four solid streaming options for Wednesday, including his stream of the day! He also goes over some recent injury news and some happenings across MLB. ***Stream of the Day Tracker*** SUBSCRIBE, Rate and Review on Apple and Spotify! Follow us on Twitter: @EthosFantasyBB Follow us on Bluesky: @ethosfantasymlb Join our Fantasy Sports Discord Server: https://discord.gg/jSwGWSHqaV

Our experts will take you through patient cases and the latest clinical data for potentially game-changing therapies for patients with IgA nephropathy (IgAN). Credit available for this activity expires: 01/03/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/emerging-iga-nephropathy-advances-digging-deep-b-cell-2024a1000pfe?ecd=bdc_podcast_libsyn_mscpedu

Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.

While housing markets play a significant role in economies, new research shows houses across 40 countries are less affordable than at any time since the 2008 financial crisis. IMF economist Deniz Igan helped develop the Housing Affordability Index. In this podcast, she says the pandemic triggered an unusual sequence of events that housing markets around the world are still struggling to correct.  Transcript: https://bit.ly/49AeK0N Read the article in Finance and Development: IMF.org/fandd

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Candid, a startup, is investing $370 million to prove the worth of bispecifics in autoimmune diseases. Summit's lung cancer drug has shown significant benefits over Keytruda, a popular immunotherapy drug. Relay's breast cancer drug also showed promise in early trials. Biotech IPOs are crucial in the industry, and their performance is being closely monitored. Early study data on Terns, a potential contender in the obesity drug market, is also discussed.Summit Therapeutics has declared victory over Keytruda in advanced non-small cell lung cancer, with their drug Ivonescimab showing a 49% higher effectiveness in reducing disease progression or death in a late-stage study. GSK is set to approach the FDA with positive Phase III data for a long-acting asthma medication. Terns Pharmaceuticals' investigational GLP-1 pill has shown promising weight loss results. Sino Biological has launched a new center for bioprocessing, and various pharmaceutical companies are making advancements in their pipelines. The FDA tracker highlights Travere's full approval for an IgAN drug.The challenges faced in the cell and gene therapy industry as it grows in popularity among investors and innovators are discussed. Shortages of brand-name diabetes and obesity medications from Novo Nordisk and Eli Lilly, such as Ozempic and Mounjaro, are due to high demand. Efforts are being made to ramp up manufacturing and develop new medications. Lilly recently made a billion-dollar deal with Haya Therapeutics to develop genetic obesity medications. The revival of drugs for Huntington's disease after initial trial failures is mentioned. Challenges in turning new drugs into successful assets even after FDA approval are highlighted, along with a poll on which presidential candidate would support policies favorable to the pharma industry. Information on staying compliant with the EU GMP Annex 1 revision is also provided.

In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients' kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.  Topics include:Supportive care as the foundation of IgAN managementPlace in therapy for new and emerging agentsTargeted-release formulation of budesonideEndothelin receptor antagonists (eg, sparsentan)Factor B inhibitors (eg, iptacopan)The role of clinical trial involvementLearn more about IgA nephropathy with educational activities and resources here:  CME-certified text module with animated pathophysiology video and patient voice audio clipClinicalThought commentariesResources on IgAN from the American Kidney Fund

Recent advances in our understanding of immunoglobulin A (IgA) nephropathy (IgAN) have led to an abundance of research into new therapies; our experts will guide you through it all. Credit available for this activity expires: 8/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001534?ecd=bdc_podcast_libsyn_mscpedu

Are your patients' kidneys fighting a silent battle? Our experts give insight on earlier detection of IgAN and react to a real patient's experience. Credit available for this activity expires: 8/23/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001513?ecd=bdc_podcast_libsyn_mscpedu

Jai Radhakrishnan, MD, MS, Getting Up to Speed in IgAN: An Expert-Led Rapid-Fire Journal Club Series

Dive into the fascinating world of immunoglobulin A nephropathy (IgAN), the most common form of primary glomerulonephritis worldwide. Credit available for this activity expires: 7/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001351?ecd=bdc_podcast_libsyn_mscpedu

In this CCO Nephrology podcast episode, hear from Kelly Chen, a nephrology nurse practitioner and patient living with IgA nephropathy, as she discusses her experiences with Dr Pietro Canetta, Associate Professor of Medicine at Columbia University and expert in glomerular diseases. Episode outline: Seeking and obtaining an IgAN diagnosis Patient self-advocacy Individualizing IgAN treatment plansClinical trial involvement Burdens of IgAN: physical, emotional, social, and beyondTo learn more about IgA nephropathy, find more educational activities and resources with the links below: CME-certified text module with animated pathophysiology video and patient voice audio clipsClinicalThought commentaries Resources on IgAN from the American Kidney Fund 

The Filtrate:Joel TopfJosh WaitzmanWith Special Guest:Brad Rovin (@BradRovin) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial. Koyal Jain (@koyaljainMD) Program director of the GN Fellowship at University of North CarolinaRoger Rodby (@NephRodby) Associate program director of the Rush University Nephrology FellowshipEditor Sophia AmbrusoShow NotesThe manuscript (The Lancet | PubMed | NephJC)The Results of Part A (Kidney Int | PubMed)Edmund (Ed) Louis memorium by Steve Korbet in KISteve Korbet Do not miss this tweet TESTING Freely Filtered #48 with Sean BarbourIptapocan at the World Congress of Nephrology: WCN24-1506 Efficacy And Safety Of Iptacopan In Patients With IgA Nephropathy: Interim Results From The Phase 3 APPLAUSE-IgAN StudyFDA and mandatory post-marketing studies. What happens when the study is negative (or not completed) (UNDARK)Who should treat lupus nephritis: rheumatologists or nephrologists? (Nature Reviews Nephrology)Protein and albumin-to-creatinine ratios in random urines accurately predict 24 h protein and albumin loss in patients with kidney disease (PubMed)MEST Scores in NephJC Risk scores in IgAN in NephJCRepeat renal biopsy improves the Oxford classification-based prediction of immunoglobulin A nephropathy outcome (NDT)Tarpeyo pills 4 mg. Four pills once a day. (WellRx has a picture of the pills)IgA nephropathy in African Americans: uncommon but possible (PubMed Central)Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don't Know (PubMed Central)Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy (JAMA Network Open)Tubular Secretions Joel: Constellation on Apple TV (Wikipedia). Not good. Dune audio books are excellent. (Audible)Josh: Podcasts about donating a kidneyOne Is Enough Podcast (National Kidney Registry)Donor Diaries (National Kidney Donation Organization)Roger Iceland (Wikipedia)Koyal India (Wikipedia)Brad Fishing in Dubai